{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:06:34Z","timestamp":1789545994108,"version":"build-2803163510"},"reference-count":60,"publisher":"Wiley","issue":"18","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The year 2025 marked significant advances in autologous cellular therapy for melanoma and solid tumors, building on landmark regulatory approvals in 2024. Lifileucel, the first Food and Drug Administration\u2010approved tumor\u2010infiltrating lymphocyte (TIL) therapy for advanced melanoma, demonstrated durable efficacy in the 5\u2010year analysis of the C\u2010144\u201001 trial, with an objective response rate (ORR) of 31.4% and prolonged responses in a heavily pretreated population. Real world data further supported its effectiveness, with higher ORR likely reflecting earlier lines of therapy and differences in patient selection. Preferentially expressed antigen in melanoma (PRAME)\u2010targeted T\u2010cell receptor (TCR) T\u2010cell therapy (anzu\u2010cel, IMA203) showed promising activity in a phase 1 study, with ORR of approximately 50% in checkpoint inhibitor refractory melanoma, durable responses, and manageable toxicity, validating PRAME as a high value target across multiple tumor types. Next\u2010generation engineered TIL approaches emerged to address limitations of high\u2010dose IL\u20102. OBX\u2010115, an IL\u20102 independent TIL platform expressing membrane\u2010bound IL\u201015 regulated by acetazolamide, demonstrated early clinical activity with ORR of 67% in initial phase 1 data. Additional strategies, including\n                    <jats:italic>CRISPR<\/jats:italic>\n                    \u2010mediated gene editing and checkpoint disruption, highlight a shift toward programmable, self\u2010sustaining cellular therapies. Personalized neoantigen\u2010based therapies advanced with early clinical validation of adoptive T\u2010cell platforms and mRNA vaccines, demonstrating immune activation and improved recurrence\u2010free survival in melanoma. Finally, afamitresgene autoleucel (afami\u2010cel), a MAGE\u2010A4 directed TCR\u2010T therapy, showed durable efficacy in synovial sarcoma and expanding activity across solid tumors, establishing proof of concept for TCR\u2010T approaches. Collectively, these advances position autologous cellular therapy as an evolving standard of care in melanoma and a promising modality across solid tumors, with ongoing efforts focused on improving accessibility, overcoming resistance, and optimizing combinatorial strategies.\n                  <\/jats:p>","DOI":"10.1002\/cncr.70612","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:16:17Z","timestamp":1789398977000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Top advances of the year in autologous cellular therapy in melanoma and solid tumors"],"prefix":"10.1002","volume":"132","author":[{"given":"Kimberly","family":"Loo","sequence":"first","affiliation":[{"name":"Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0238-7133","authenticated-orcid":false,"given":"Allison S.","family":"Betof","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201000765"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.04.044"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9607"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201023\u20101334"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157151"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010025\u201003650\u20106"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.2508"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS2673"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqab200"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001944"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201025\u20100278"},{"key":"e_1_2_5_13_1","unstructured":"Immatics highlights compelling anti\u2010tumor activity of anzu\u2010cel PRAME cell therapy in metastatic uveal melanoma at the ESMO 2025 Presidential Symposium. Accessed May 18 2026.https:\/\/investors.immatics.com\/news\u2010releases\/news\u2010release\u2010details\/immatics\u2010highlights\u2010compelling\u2010anti\u2010tumor\u2010activity\u2010anzu\u2010cel\/"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad078"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102023\u2010008735"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(25)00434\u20106"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.04.031"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9599"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.9507"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.9517"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.AM2025\u2010CT244"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163096"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.AM2025\u20102196"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102025\u2010SITC2025.0569"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1009"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2552"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18010144"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010025\u201001732\u2010z"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)00553\u20107"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003418\u20104"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010026\u201068680\u20101"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)02268\u20107"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9616"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1617654"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201024\u20104146"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201025\u20100595"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)00319\u20102"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2025.2612043"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349\u20107006.2009.01303.x"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104099"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201006\u20100527"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010022\u201002128\u2010z"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201024\u201001466"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114224"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416\u2010026\u201003350\u2010z"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12964\u2010025\u201002632\u2010y"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326\u20106066.CIR\u201016\u20100043"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199486"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.11.014"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/10430342251372041"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.10.027"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417\u2010019\u20100104\u2010z"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018\u2010023\u201000628\u20106"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.11.018"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.12.014"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.07.020"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010021\u201000462\u20101"},{"key":"e_1_2_5_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13059\u2010023\u201002928\u20107"},{"issue":"19","key":"e_1_2_5_61_1","article-title":"SUPRAME: a phase 3 trial comparing IMA203, an engineered T\u2010cell receptor expressing T cell therapy (TCR\u2010T) vs investigator\u2019s choice in patients with previously treated advanced cutaneous melanoma","volume":"43","author":"Luke JJ","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70612","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70612","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:40:44Z","timestamp":1789544444000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":60,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,15]]}},"alternative-id":["10.1002\/cncr.70612"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70612","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"2026-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70612"}}